Conference Call, Presentation of Drug Trial Results, Breakthrough Therapy Designation, Positive Results, and Drug Revival - Research Report on Johnson & Johnson, Lilly, GSK, Kythera, and Sanofi

Editor Note: For more information about this release, please scroll to bottom

News provided by

Sep 20, 2013, 08:00 ET

NEW YORK, September 20, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline plc (NYSE: GSK), KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH), and Sanofi (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 17, 2013, Johnson & Johnson announced that it will host its Q3 2013 conference call on October 15, 2013 at 8:30 a.m. ET. The Company reported that the call will be hosted by Michel Orsinger, Worldwide Chairman of DePuy Synthes Companies; Dominic J. Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations. According to Johnson & Johnson, interested parties may access the conference call through its Investor Relations website, mobile application for iPad and iPhone users, and telephone by using the dial-in details. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-17/JNJ]

Eli Lilly and Company Research Report

On September 17, 2013, Eli Lilly and Company (Lilly) announced that it will present a total of 31 abstracts during the upcoming 49th European Association for the Study of Diabetes Annual Meeting in Barcelona, taking place from September 23 to September 27, 2013. According to Lilly, it will present the Phase III data for dulaglutide (investigational GLP-1 receptor agonist) and the Phase II data for LY2605541 (investigational novel basal insulin analog) in seven presentations. The Company also reported that it will present an additional seven abstracts, including research from its early-stage pipeline, while the Boehringer Ingelheim will present seventeen abstracts on behalf of the Alliance with Lilly. The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-17/LLY]

GlaxoSmithKline plc Research Report

On September 13, 2013, GlaxoSmithKline plc (GSK) and Genmab A/S announced that the US Food and Drug Administration (FDA) has granted Arzerra (ofatumumab) a Breakthrough Therapy designation. GSK reported that the designation was specifically for Arzerra in combination with chlorambucil for the treatment of chronic lymphocytic leukaemia (CLL) patients who have not received prior treatment and are inappropriate for fludarabine-based therapy. Dr. Kathy Rouan, Vice President and Head of Biopharmaceutical Development at GSK stated, "We are exceedingly proud to receive the Breakthrough Therapy designation, the second this year for GSK. This FDA programme is intended to expedite not just the development but also the review of drugs for serious or life threatening conditions. We are actively working on our submission and look forward to the enhanced regulatory interaction allowed for Breakthrough Therapies." The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-17/GSK]

KYTHERA Biopharmaceuticals, Inc. Research Report

On September 16, 2013, KYTHERA Biopharmaceuticals, Inc. (Kythera) announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. According to the Company, the Phase III trials were conducted in the US and Canada to compare the efficacy and safety of a 2 mg/cm^[²^] dose of ATX-101 versus placebo for the reduction of submental fat, which commonly presents as a double chin. Frederick Beddingfield, III, M.D., Ph.D., Chief Medical Officer of Kythera, stated, "The strong results from REFINE-1 and REFINE-2 are incredibly exciting and consistent with the profile of ATX-101 based on previous data." Beddingfield continued, "We look forward to discussing submission plans with U.S. and Canadian regulatory authorities in the near future. If approved, ATX-101 will represent a significant innovation in the category of aesthetic medicine." The Full Research Report on KYTHERA Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-17/KYTH]

Sanofi Research Report

On September 16, 2013, Sanofi announced that Sanofi US and its consumer health business Chattem, Inc. (Chattem) re-introduced Rolaids® in the US after a gap of three years. According to Sanofi, the re-launch follows Chattem's acquisition of Rolaids from McNeil Consumer Healthcare Division of McNEIL-PPC, Inc., which was completed on January, 7, 2013. Zan Guerry, CEO of Chattem, said, "For the last few years there has been a significant gap in the over-the-counter antacid marketplace here in the U.S. Starting today, the millions of people who suffer from frequent heartburn and acid indigestion can once again turn to Rolaids to help relieve their symptoms." Anne Whitaker, President of North America Pharmaceuticals, Sanofi, commented, "Incorporating Rolaids into Chattem's portfolio further strengthens Sanofi's position as a leader in the U.S. consumer healthcare sector and helps to further diversify our category offerings." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-17/SNY]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

InvestorsReports.com

SOURCE Investors' Reports